Dermata Therapeutics, Inc. (DRMAW) has a negative trailing P/E of -0.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -480.69%.
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -0.9 | 0.00 | -20.57 | 0.00 | - |
| 2020 | -1.3 | 0.00 | -1.36 | 0.00 | - |
| 2021 | -2.8 | 0.03 | 2.15 | 0.00 | - |
| 2022 | -0.7 | 0.08 | 1.13 | 0.00 | - |
| 2023 | 0.0 | 0.00 | 0.03 | 0.00 | - |
| 2024 | 0.0 | 0.00 | 0.13 | 0.00 | - |
| 2025 | -0.3 | 0.00 | 0.00 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-9.55 | $0.00 | $-4.97M | - |
| 2020 | $-6.60 | $0.00 | $-3.24M | - |
| 2021 | $-15.27 | $0.00 | $-7.9M | - |
| 2022 | $-13.92 | $0.00 | $-9.61M | - |
| 2023 | $-39.98 | $0.00 | $-7.8M | - |
| 2024 | $-8,032.22 | $0.00 | $-12.29B | - |
| 2025 | $-8.16 | $0.00 | $-7.56M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.01 | $-3.01 – $-3.01 | $15M | $15M – $15M | 1 |
| 2027 | $0.00 | $0.00 – $0.00 | $750K | $750K – $750K | 0 |
